Orion S.A.OECEarnings & Financial Report
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
OEC Q1 FY2026 Key Financial Metrics
Revenue
$459.5M
Gross Profit
$79.2M
Operating Profit
$11.4M
Net Profit
$-9.9M
Gross Margin
17.2%
Operating Margin
2.5%
Net Margin
-2.2%
YoY Growth
-3.8%
EPS
$-0.18
Orion S.A. Q1 FY2026 Financial Summary
Orion S.A. reported revenue of $459.5M (down 3.8% YoY) for Q1 FY2026, with a net profit of $-9.9M (down 208.8% YoY) (-2.2% margin). Cost of goods sold was $380.3M, operating expenses totaled $67.8M.
Key Financial Metrics
| Total Revenue | $459.5M |
|---|---|
| Net Profit | $-9.9M |
| Gross Margin | 17.2% |
| Operating Margin | 2.5% |
| Report Period | Q1 FY2026 |
Orion S.A. Annual Revenue by Year
Orion S.A. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.8B).
Orion S.A. Quarterly Revenue & Net Profit History
Orion S.A. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $459.5M | -3.8% | $-9.9M | -2.2% |
| Q4 FY2025 | $411.7M | -5.2% | N/A | N/A |
| Q3 FY2025 | $450.9M | -2.7% | $-67.1M | -14.9% |
| Q2 FY2025 | $466.4M | -2.2% | $9.0M | 1.9% |
| Q1 FY2025 | $477.7M | -5.0% | $9.1M | 1.9% |
| Q4 FY2024 | $434.2M | -7.3% | N/A | N/A |
| Q3 FY2024 | $463.4M | -0.6% | $-20.2M | -4.4% |
| Q2 FY2024 | $477.0M | +4.0% | $20.5M | 4.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $477.0M | $463.4M | $434.2M | $477.7M | $466.4M | $450.9M | $411.7M | $459.5M |
| YoY Growth | 4.0% | -0.6% | -7.3% | -5.0% | -2.2% | -2.7% | -5.2% | -3.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.91B | $2.00B | $1.86B | $1.97B | $2.02B | $1.96B | $1.91B | $1.93B |
| Liabilities | $1.40B | $1.52B | $1.38B | $1.50B | $1.56B | $1.56B | $1.52B | $1.55B |
| Equity | $503.9M | $476.3M | $474.9M | $466.1M | $466.5M | $401.8M | $384.6M | $379.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $29.3M | $-30.9M | $94.5M | $400000 | $53.7M | $68.8M | $92.9M | $-12.4M |